TRIAL DETAIL
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 01/01/2008 |
Age of Trial (yrs) 16.3 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
IGF1R inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
212ST101 |
|||
Sponsor: |
Biogen Idec |
|||
Patient Contact: |
Biogen Idec
oncologyclinicaltrials@biogenidec.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
Excludes patients who have received prior IGF-1R inhibitor therapy. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1665 N. Ursula St. |
Aurora |
CO |
80045 |
USA |
|
333 Cottman Ave |
Philadelphia |
PA |
19111 |
USA |
|
Los Angeles |
CA |
USA |